Citation: Usman Mahmood, David W Johnson, Magid A Fahim. Cardiac biomarkers in dialysis[J]. AIMS Genetics, 2017, 4(1): 1-20. doi: 10.3934/genet.2017.1.1
[1] | Noel Pabalan, Neetu Singh, Eloisa Singian, Caio Parente Barbosa, Bianca Bianco, Hamdi Jarjanazi . Associations of CYP1A1 gene polymorphisms and risk of breast cancer in Indian women: a meta-analysis. AIMS Genetics, 2015, 2(4): 250-262. doi: 10.3934/genet.2015.4.250 |
[2] | Khalid Eltahir Khalid . Vitamin D receptor gene polymorphisms in Sudanese children with type 1 diabetes. AIMS Genetics, 2016, 3(3): 167-176. doi: 10.3934/genet.2016.3.167 |
[3] | Harem Othman Smail . The epigenetics of diabetes, obesity, overweight and cardiovascular disease. AIMS Genetics, 2019, 6(3): 36-45. doi: 10.3934/genet.2019.3.36 |
[4] | Mohammad Hashemi, Fatemeh Bizhani, Hiva Danesh, Behzad Narouie, Mehdi Sotoudeh, Mohammad Hadi Radfar, Mehdi Honarkar Ramezani, Gholamreza Bahari, Mohsen Taheri, Saeid Ghavami . MiR-608 rs4919510 C>G polymorphism increased the risk of bladder cancer in an Iranian population. AIMS Genetics, 2016, 3(4): 212-218. doi: 10.3934/genet.2016.4.212 |
[5] | Harem Othman Smail . The roles of genes in the bitter taste. AIMS Genetics, 2019, 6(4): 88-97. doi: 10.3934/genet.2019.4.88 |
[6] | Alena V Malakhova, Olga I Rudko, Vladimir V Sobolev, Artemii V Tretiakov, Elena A Naumova, Zarema G Kokaeva, Julia E Azimova, Eugene A Klimov . PDE4B gene polymorphism in Russian patients with panic disorder. AIMS Genetics, 2019, 6(3): 55-63. doi: 10.3934/genet.2019.3.55 |
[7] | Carina Ladeira, Susana Viegas, Mário Pádua, Elisabete Carolino, Manuel C. Gomes, Miguel Brito . Relation between DNA damage measured by comet assay and OGG1 Ser326Cys polymorphism in antineoplastic drugs biomonitoring. AIMS Genetics, 2015, 2(3): 204-218. doi: 10.3934/genet.2015.3.204 |
[8] | Tú Nguyen-Dumont, Jenna Stewart, Ingrid Winship, Melissa C. Southey . Rare genetic variants: making the connection with breast cancer susceptibility. AIMS Genetics, 2015, 2(4): 281-292. doi: 10.3934/genet.2015.4.281 |
[9] | Carina Ladeira, Lenka Smajdova . The use of genotoxicity biomarkers in molecular epidemiology: applications in environmental, occupational and dietary studies. AIMS Genetics, 2017, 4(3): 166-191. doi: 10.3934/genet.2017.3.166 |
[10] | Vladlena Tiasto, Valeriia Mikhailova, Valeriia Gulaia, Valeriia Vikhareva, Boris Zorin, Alexandra Kalitnik, Alexander Kagansky . Esophageal cancer research today and tomorrow: Lessons from algae and other perspectives. AIMS Genetics, 2018, 5(1): 75-90. doi: 10.3934/genet.2018.1.75 |
The variable coefficient homogeneous differential equations (VCHDE) provide a more vivid and comprehensive description of various phenomena and processes in the real world. Specifically, VCHDE are commonly applied in the study of fluctuation equations in physics to describe the propagation of fluctuations within a medium, where the variable coefficients are related to the density, elastic modulus, and other properties of the medium. For instance, they are used to derive design methods for high-resolution imaging optical systems [1]. Thus, exploring the existence of solutions to VCHDE is crucial for their broader applications.
In many early studies, certain progress had been made in researching the existence of solutions to lower-order VCHDE. Zhao and Ma applied the Leray–Schauder extension theorem to study a class of nonlinear fourth-order ordinary differential equation boundary value problems, obtaining existence results for the solutions [2]. Zhang et al. extended some results concerning the estimation of the growth of the full solution of a certain class of two-linear differential equations to nonlinear two-linear differential equations [3]. Yang and Chen et al. found the existence of solutions to impulsive mixed boundary value problems involving derivatives of Caputo fractions and Krasnoselskii's fixed point theorem, and the Arzela–Ascoli theorem gave some examples to illustrate the main results [4]. Alyusof and Jeelani et al. used the technical method of factorization to derive properties such as partial dichotomy, several properties of dichotomy of polynomials, partial differential expressions for Gould–Hopper–Frobenius–Genocchi polynomials, etc. [5]. Tian and Chen et al. obtained the general solution formula for the corresponding second-order second derivative equation from the prime decomposition of a quadratic matrix polynomial and the general solution formula for the corresponding second-order disjunctive equation [6]. Hasil and Vesel' et al. used the Riccati transformation, identified a new type of conditionally oscillatory linear differential equations together with the critical oscillation constant, and proved that they remained conditionally oscillatory with the same critical oscillation constant [7]. Bazighifan et al. studied the oscillation of solutions for a fourth-order neutral nonlinear differential equation, driven by a p-Laplace differential operator and obtained an oscillatory criterion for these equations [8]. Zheng et al. introduced the elastic transformation method into the process of solving ordinary differential equations. A class of first-order and a class of third-order ordinary differential equations with variable coefficients could be transformed into the Laguerre equation through elastic transformation. The general solution of these two types of ordinary differential equations was obtained [9]. Soto et al. studied a class of singular nonlinear partial differential equations and constructed unique solutions that were continuous in a certain interval [10]. According to the properties and initial conditions of the Chebyshev polynomials, Fan et al. could obtain the solutions of the initial value problems of the original first-order differential equations and the third-order differential equations by the elastic inverse transformation and then plot the curves [11]. Fan et al. studied the positive solutions of the periodic-parabolic logistic equation with indefinite weight function and a non homogeneous diffusion coefficient, and obtained the existence, uniqueness, and stability of positive periodic solutions [12]. Zhang et al. studied the initial value problem for higher-order Caputo type modified nonlinear differential equations with Erdelyi–Kober fractional derivatives. According to the transmutation method, the good solvability of the initial value problem for higher-order linear models was proved and explicit solutions were given. Some new Gronwall-type inequalities involving Erdelyi–Kober fractional integrals were then established. By applying these results and some fixed point theorems, the existence and uniqueness of positive solutions of nonlinear differential equations were proved [13]. The results of Albidah et al. showed that the solution was continuous in the domain of the problem in the limit of the given initial conditions, whereas the first-order derivatives were discontinuous at a point and lay in the domain of the delay equation [14]. Al-Mazmumy et al. improved the standard Adomian decomposition method by combining Taylor series with orthogonal polynomials [15]. Bendouma et al. investigated the existence of solutions to a system of fourth-order differential equations when a function lay on the right-hand side. The concept of a solution tube was proposed for these problems. According to this concept, the concepts of the upper and lower solutions of fourth-order differential equations were extended to systems of fourth-order differential equations [16]. Wang et al. studied a certain higher-order uncertain differential equation, focusing mainly on the second-order case. We introduced the notion of a path for uncertain differential equations and proved its properties. On this basis, we derived the inverse uncertainty distribution of the solution [17]. AlKandari et al. studied a certain oscillatory behaviour of the solutions of a class of multi-delayed third-order neutral differential equations and proposed a new oscillatory criterion that refined and simplified some previous results [18]. Turo et al. proved an existence and uniqueness theorem for first-order stochastic partial differential equations [19]. Zhang et al. numerically investigated the spatially variable coefficient fractional convection–diffusion wave equation with single and multiple delays when the exact solution satisfied certain regularities [20]. Borrego-Morell et al. studied linear second-order differential equations. Under some assumptions on a certain class of descending and ascending operators, it was shown that, for a certain sequence of polynomials to be orthogonal on the unit circle in order to satisfy the differential equations, the polynomials must be of a particular form involving extensions of Gaussian and confluent hypergeometric series [21]. Akhmetkaliyeva et al. considered the third-order differential equation with unconstrained coefficients, proved some new existence and uniqueness results, and gave exact estimates of the norm of the solution [22]. Padhi et al. obtained sufficient conditions for the existence of at least two non-negative periodic solutions for a system of first-order nonlinear functional differential equations, giving some applications to ecological [23]. Mohamed et al. studied the conditions under which Schrödinger-type operators with matrix potentials were separated and the Schrödinger equation had a unique solution in a weighted space [24]. Khaliq et al. presented a series of second-order methods for the numerical solution of fourth-order parabolic partial differential equations with variable coefficients in one spatial variable [25]. Mohammed et al. introduced a class of second-order ordinary differential equations with variable coefficients whose closed-form solutions could be obtained by the same methods used to solve differential equations with constant coefficients. General solutions in the homogeneous case were also discussed [26]. Lynch et al. presented a large class of second-order variable coefficient ordinary differential equations with known solutions. This class of equations formed the basis of a large number of examples that could be used to explore the theory of solutions to linear differential equations [27]. Camporesi et al. proposed an impulse response method based on the factorization of differential operators for solving linear ordinary differential equations with constant coefficients [28]. Jia et al. used the relationship between the higher-order variable coefficients, the conditions for constant coefficient of the fifth-order variable coefficient linear non-homogeneous equations were obtained by appropriate linear transformations [29]. To sum up, although these research achievements have made some contributions in the field of lower-order VCHDE, there is still much room for exploration in the research of higher-order VCHDE, especially in the aspect of extending the conditions for the existence of particular solutions to higher orders.
Generally speaking, previous research efforts have predominantly concentrated on lower-order VCHDE. The investigations into second-order and third-order VCHDE have, to a certain degree, established the groundwork and proffered ideas for higher-order scenarios. However, fourth-order VCHDE are far more intricate than their second-order and third-order counterparts, and frequently manifests in practical applications. For instance, Hu and Li et al. [30] furnished the sufficient conditions for the existence of polynomial particular solutions for a class of second-order linear VCHDE with polynomial coefficients through recursive formulas. Subsequently, Li and Jiang et al. [31] leveraged the concept of coefficient matrices to deduce the solutions of third-order linear VCHDE with polynomial coefficients, building upon the work of Hu et al. [30]. Notably, although fourth-order VCHDE are typically more complex than second or third order ones, they are inescapable in certain problems. This present work, for the first time, extends the necessary and sufficient conditions for the existence of particular solutions of VCHDE to the fourth-order and nth-order cases. By delving into the relationship between the coefficient matrix of the VCHDE and the existence of polynomial particular solutions, the necessary and sufficient conditions for the existence of solutions of fourth-order VCHDE and those for the nth-order VCHDE are derived. In this way, we are able to address the problem of the existence of solutions of VCHDE with polynomial coefficients for any order. It should be emphasized that although the ultimate conclusion pertains to the nth-order case, the exploration of the fourth-order VCHDE is indispensable. The fourth-order case serves as a crucial stepping-stone, bridging the gap between the lower-order studies and generalization to the nth-order, providing valuable insights and intermediate results that are essential for the overall theoretical framework.
The paper is organized as follows: Section 2 derives the existence of solutions to fourth-order VCHDE, Section 3 proves the existence of solutions to nth-order VCHDE, and Section 4 provides the discussion and conclusion.
In this section, we study the existence of particular solutions to fourth-order VCHDE subject to the following constraints.
Lemma 1. Let A be an n×m matrix and let X be an m-dimensional column vector. There then exists a non-zero solution X∗=0 to the system of homogeneous linear equations AX=0, and the sufficient and necessary condition that its first component is not zero is:
rank(ˆA)=rank(A), |
where ˆA is the submatrix of A minus the first column.
Now, the existence of solutions of fourth-order VCHDE is investigated
P(x)y⁗+Q(x)y‴+R(x)y″+S(x)y′+T(x)y=0, | (2.1) |
based on the Lemma, where the coefficients of the differential equation are
(P(x)Q(x)R(x)S(x)T(x))=[k1,nk1,n−1⋯k1,1k1,0k2,nk2,n−1⋯k2,1k2,0k3,nk3,n−1⋯k3,1k3,0k4,nk4,n−1⋯k4,1k4,0k5,nk5,n−1⋯k5,1k5,0](xnxn−1⋮x1), | (2.2) |
where ki,j(i=1,2,3,4,5. j=0,1,…,n) is a constant.
Theorem 1. A necessary and sufficient condition for the existence of a particular solution of the polynomial type of the mth-order for the VCHDE (2.1) with fourth-order polynomial coefficients (where the coefficients are given by (2.2)) is
k5,n=0,rank(^Fm)=rank(Fm), |
where Fm is the (m+n)×(m+1) matrix.
Fm=[mk4,n+k5,n−1k5,n0⋯0A2mk3,n+mk4,n−1+k5,n−2A3mk2,n+A2mk3,n−1+mk4,n−2+k5,n−3A4mk1,n+A3mk2,n−1+A2mk3,n−2+mk4,n−3+k5,n−4A4mk1,n−1+A3mk2,n−2+A2mk3,n−3+mk4,n−4+k5,n−5⋮Fm−1A4mk1,4+A3mk2,3+A2mk3,2+mk4,1+k5,0A4mk1,3+A3mk2,2+A2mk3,1+mk4,0A4mk1,2+A3mk2,1+A2mk3,0A4mk1,1+A3mk2,0A4mk1,00⋮0], |
F1=[k4,n+k5,nk5,nk4,n−1+k5,n−1k5,n−1⋮⋮k4,1+k5,1k5,1k4,0k5,0]. |
Proof. Let the coefficients be nth-degree polynomials, i.e.,
(P(x)Q(x)R(x)S(x)T(x))=[k1,nk1,n−1⋯k1,1k1,0k2,nk2,n−1⋯k2,1k2,0k3,nk3,n−1⋯k3,1k3,0k4,nk4,n−1⋯k4,1k4,0k5,nk5,n−1⋯k5,1k5,0](xnxn−1⋮x1). | (2.2) |
When m=1, the equation is assumed to have a first-order solution
y=K1x+K0, |
where Ki(i=0,1) is a constant. Substituting this into Eq (2.1) yields
P(x)y′′′′+Q(x)y′′′+R(x)y′′+S(x)y′+T(x)y=K1k5,nxn+1+(xnxn−1⋯1)[k4,n+k5,nk5,nk4,n−1+k5,n−1k5,n−1⋮⋮k4,1+k5,1k5,1k4,0k5,0][K1K0]. |
Let
F1=[k4,n+k5,nk5,nk4,n−1+k5,n−1k5,n−1⋮⋮k4,1+k5,1k5,1k4,0k5,0]. |
The sufficient condition for the existence of a first-order solution to Eq (2.1) with coefficients (2.2) is given by the Lemma
k5,n=0,rank(F1)=rank(F0). |
When m=2, the equation is assumed to have a second-order solution
y=K2x2+K1x+K0, |
where Ki(i=0,1,2.) is a constant. Substituting this into Eq (2.1) yields
P(x)y′′′′+Q(x)y′′′+R(x)y′′+S(x)y′+T(x)y=K2k5,nxn+2+(xn+1xn⋯x1)[2k4,n+k5,n−1k5,n02k4,n−1+k5,n−2⋮F1k4,1+k5,1k4,0][K2K1K0]. |
Let
F2=[2k4,n+k5,n−1k5,n02k4,n−1+k5,n−2⋮F1k4,1+k5,1k4,0]. |
The sufficient condition for the existence of an mth-order solution to Eq (2.1) with coefficients (2.2) is given by the lemma
k5,n=0,rank(F2)=rank(F1). |
By analogy, the equation is assumed to have mth-order solutions when m≥4
y=Kmxm+Km−1xm−1+⋯+K1x+K0, |
where Ki(i=0,1,…,m.) is a constant. Substituting this into Eq (2.1) yields
P(x)y′′′′+Q(x)y′′′+R(x)y′′+S(x)y′+T(x)y=Kmk5,nxm+n+(xn+m−1xn+m−2⋯xm−3xm−4)×[mk4,n+k5,n−1k5,n0⋯0A2mk3,n+mk4,n−1+k5,n−2A3mk2,n+A2mk3,n−1+mk4,n−2+k5,n−3A4mk1,n+A3mk2,n−1+A2mk3,n−2+mk4,n−3+k5,n−4A4mk1,n−1+A3mk2,n−2+A2mk3,n−3+mk4,n−4+k5,n−5⋮Fm−1A4mk1,4+A3mk2,3+A2mk3,2+mk4,1+k5,0A4mk1,3+A3mk2,2+A2mk3,1+mk4,0A4mk1,2+A3mk2,1+A2mk3,0A4mk1,1+A3mk2,0A4mk1,00⋮0][KmKm−1⋮K1K0]. |
Let
Fm=[mk4,n+k5,n−1k5,n0⋯0A2mk3,n+mk4,n−1+k5,n−2A3mk2,n+A2mk3,n−1+mk4,n−2+k5,n−3A4mk1,n+A3mk2,n−1+A2mk3,n−2+mk4,n−3+k5,n−4A4mk1,n−1+A3mk2,n−2+A2mk3,n−3+mk4,n−4+k5,n−5⋮Fm−1A4mk1,4+A3mk2,3+A2mk3,2+mk4,1+k5,0A4mk1,3+A3mk2,2+A2mk3,1+mk4,0A4mk1,2+A3mk2,1+A2mk3,0A4mk1,1+A3mk2,0A4mk1,00⋮0]. |
In summary, it follows from the lemma that the sufficient condition for the existence of a particular solution to this VCHDE is
k5,n=0,rank(^Fm)=rank(Fm). |
Proof completed (PC).
The existence of unique solutions to this fourth-order VCHDE is investigated next.
Theorem 2. When k4,n≠0, there is a unique number of polynomial particular solutions to VCHDE (2.1) with fourth-order polynomial coefficients of (2.2).
Proof. By Theorem 1, the differential Eq (2.1) has mth-order polynomial particular solutions if and only if
k5,n=0,rank(^Fm)=rank(Fm), |
where
Fm=[mk4,n+k5,n−1k5,n0⋯0A2mk3,n+mk4,n−1+k5,n−2A3mk2,n+A2mk3,n−1+mk4,n−2+k5,n−3A4mk1,n+A3mk2,n−1+A2mk3,n−2+mk4,n−3+k5,n−4A4mk1,n−1+A3mk2,n−2+A2mk3,n−3+mk4,n−4+k5,n−5⋮Fm−1A4mk1,4+A3mk2,3+A2mk3,2+mk4,1+k5,0A4mk1,3+A3mk2,2+A2mk3,1+mk4,0A4mk1,2+A3mk2,1+A2mk3,0A4mk1,1+A3mk2,0A4mk1,00⋮0]. |
It is clear that f11=mk4,n+k5,n−1, f1j=0, j=2,3,…,m−1 in the matrix Fm=(fij).
Then from rank(^Fm)=rank(Fm), we conclude
mk4,n+k5,n−1=0. |
In other words,
m=−k5,n−1k4,n∈N+, |
and the other elements on the diagonal of the matrix Fm satisfy
lk4,n+k5,n−1≠0,l=0,1,…,m−1. |
Otherwise, it does not satisfy rank(^Fm)=rank(Fm),
where we let ¯Fm be the matrix obtained by removing the first row of Fm.
Thus
¯Fm=[A2mk3,n+mk4,n−1+k5,n−2A3mk2,n+A2mk3,n−1+mk4,n−2+k5,n−3A4mk1,n+A3mk2,n−1+A2mk3,n−2+mk4,n−3+k5,n−4A4mk1,n−1+A3mk2,n−2+A2mk3,n−3+mk4,n−4+k5,n−5⋮A4mk1,4+A3mk2,3+A2mk3,2+mk4,1+k5,0Fm−1A4mk1,3+A3mk2,2+A2mk3,1+mk4,0A4mk1,2+A3mk2,1+A2mk3,0A4mk1,1+A3mk2,0A4mk1,00⋮0]. |
It is clear that rank(Fm)=rank(¯Fm)=m.
Subject to the above conditions, the VCHDE (2.1) has mth-order polynomial particular solutions.
Proof completed (PC).
The proof of Theorem 2 includes the proof of the following corollary, so by the same reasoning.
Corollary 1. When k4,n≠0, the sufficiently and necessary condition for the existence of mth-order polynomial particular solutions to the fourth-order VCHDE (2.1) with the coefficients (2.2) is
m=−k5,n−1k4,n∈N+,rank(¯Fm)=m, |
where we let ¯Fm be the matrix obtained by removing the first row of Fm.
Theorem 3. When k3,n≠0, the sufficient and necessary condition for the coefficients (2.2) of fourth-order VCHDE (2.1) to have two linearly independent particular solutions is
k4,n=k5,n=k5,n−1=0, |
and
h(x)=A2xk3,n+xk4,n−1+k5,n−2, |
has two positive integer roots m1,m2, where m1≠m2, and
rank(Fm1)=rank(Fm1−1),rank(Fm2)=rank(Fm2−1). |
Proof. With loss of generality, we can assume that m1<m2. By Theorems 1 and 2, the equation with coefficients of (2.2) has two linearly independent particular solutions if and only if
k5,n=0,k4,n=0,rank(^Fm)=rank(Fm),m=m1,m2. |
In other words,
mk4,n+k5,n−1=0. |
Thus
k5,n−1=0. |
So under the above condition, the constraints at this point have
Fm=[00⋯0A2mk3,n+mk4,n−1+k5,n−2A3mk2,n+A2mk3,n−1+mk4,n−2+k5,n−3A4mk1,n+A3mk2,n−1+A2mk3,n−2+mk4,n−3+k5,n−4A4mk1,n−1+A3mk2,n−2+A2mk3,n−3+mk4,n−4+k5,n−5⋮Fm−1A4mk1,4+A3mk2,3+A2mk3,2+mk4,1+k5,0A4mk1,3+A3mk2,2+A2mk3,1+mk4,0A4mk1,2+A3mk2,1+A2mk3,0A4mk1,1+A3mk2,0A4mk1,00⋮0]. |
It is clear that for Fm=(fij), we have fii=0, fi,i+1=0, for i=1,2,…,m, and
rank(Fm1−1)=rank(^Fm1),rank(Fm2−1)=rank(^Fm2), |
from rank(Fm1)=rank(^Fm1) and rank(Fm2)=rank(^Fm2), we obtain
rank(Fm1)=rank(Fm1−1),rank(Fm2)=rank(Fm2−1), |
A2m1k3,n+m1k4,n−1+k5,n−2=0, |
A2m2k3,n+m2k4,n−1+k5,n−2=0, |
In other words,
h(m1)=0,h(m2)=0. |
Because h(x) is a quadratic polynomial, m1,m2 are exactly two different positive integer roots of h(x).
Proof completed (PC).
Using the same ideas and methods as in Theorem 3, we continue to explore the rank of the coefficient matrix Fm, proving the following corollary, so by the same reasoning.
Corollary 2. When k2,n≠0, the sufficiently and necessary condition for a fourth-order VCHDE (2.1) with the coefficients (2.2) to have three linearly independent particular solutions is
k4,n=k5,n=k5,n−1=0, |
k3,n=k4,n−1=k5,n−2=0, |
h1(x)=A3xk2,n+A2xk3,n−1+xk4,n−2+k5,n−3, |
where there exist three positive integer roots m1,m2,m3, where m1,m2,m3 are pairwise distinct, and
rank(Fm1)=rank(Fm1−2),rank(Fm2)=rank(Fm2−2),rank(Fm3)=rank(Fm3−2). |
Corollary 3. When k1,n≠0, the sufficiently and necessary condition for a fourth-order VCHDE (2.1) with the coefficients (2.2) to have four linearly independent particular solutions is
k4,n=k5,n=k5,n−1=0, |
k3,n=k4,n−1=k5,n−2=0, |
k2,n=k3,n−1=k4,n−2=k5,n−3=0, |
h2(x)=A4xk1,n+A3xk2,n−1+A2xk3,n−2+xk4,n−3+k5,n−4, |
where there exist four positive integer roots m1,m2,m3,m4, where m1,m2,m3,m4 are pairwise distinct, and
rank(Fm1)=rank(Fm1−3),rank(Fm2)=rank(Fm2−3),rank(Fm3)=rank(Fm3−3),rank(Fm4)=rank(Fm4−3). |
In this section, we study the existence of solutions to VCHDE of the nth-order.
Pn(x)y(n)+Pn−1(x)y(n−1)+⋯+P1(x)y′+P0(x)y=0, | (3.1) |
where the coefficients of the VCHDE are
(Pn(x)Pn−1(x)⋮P1(x)P0(x))=[k1,nk1,n−1…k1,1k1,0k2,nk2,n−1…k2,1k2,0⋮⋮⋱⋮⋮kn,nkn,n−1…kn,1kn,0kn+1,nkn+1,n−1…kn+1,1kn+1,0](xnxn−1⋮x1). | (3.2) |
We extend the conclusions for all particular solutions of VCHDE of the fourth-order to VCHDE of the nth-order.
Theorem 4. A necessary and sufficient condition for the existence of a particular solution of the polynomial type of the mth-order for the VCHDE (3.1) with nth-order polynomial coefficients (where the coefficients are given by (3.2)) is
kn+1,n=0,rank(^Fm)=rank(Fm), |
where Fm is the (m+n)×(m+1) matrix.
Fm=
[mkn,n+kn+1,n−1kn+1,n0⋯0A2mkn−1,n+mkn,n−1+kn+1,n−2A3mkn−2,n+A2mkn−1,n−1+mkn,n−2+kn+1,n−3⋮Anmk1,n+An−1mk2,n−1+⋯+A3mkn−2,3+A2mkn−1,2+mkn,1+kn+1,0Fm−1Anmk1,n−1+An−1mk2,n−2+⋯+A3mkn−2,2+A2mkn−1,1+mkn,0Anmk1,n−2+An−1mk2,n−3+⋯+A3mkn−2,1+A2mkn−1,0⋮Anmk1,00⋮0], |
F1=[kn,n+kn+1,nkn+1,nkn,n−1+kn+1,n−1kn+1,n−1⋮⋮kn,1+kn+1,1kn+1,1kn,0kn+1,0]. |
Proof. If there exist mth-order polynomial particular solutions to the nth-order VCHDE (3.1) with the coefficients (3.2)
y=Kmxm+Km−1xm−1+…+K1x+K0, |
where Ki(i=0,1,…,m) is a constant.
For ease of computation, without loss of generality, let us assume m≥n>0. Then bringing y into the Eq (3.1) yields
Pn(x)y(n)+Pn−1(x)y(n−1)+⋯+P1(x)y′+P0(x)y=Km[AnmPn(x)xm−n+An−1mPn−1(x)xm−n+1+⋯+mP1(x)xm−1+P0(x)xm]+Em−1 |
=Kmkn+1,nxm+n+Km[Anm(xmxm−1⋯xm−n+1xm−n)(k1,nk1,n−1⋮k1,0k1,0) |
+An−1m(xm+1xm⋯xm−n+2xm−n+1)(k2,nk2,n−1⋮k2,1k2,0)+⋯ |
+m(xn+m−1xn+m−2...xmxm−1)(kn,nkn,n−1⋮kn,1k4,0) |
+(xn+m−1xn+m−2⋯xm+1xm)(kn+1,n−1kn+1,n−2⋮kn+1,1kn+1,0)+Em−1 |
=Kmkn+1,nxm+n+(xn+m−1xn+m−2⋯xm−n+1xm−n)Fm(KmKm−1⋮K1K0), |
where Fm is the (m+n)×(m+1) matrix.
Fm=
[mkn,n+kn+1,n−1kn+1,n0⋯0A2mkn−1,n+mkn,n−1+kn+1,n−2A3mkn−2,n+A2mkn−1,n−1+mkn,n−2+kn+1,n−3⋮Anmk1,n+An−1mk2,n−1+⋯+A3mkn−2,3+A2mkn−1,2+mkn,1+kn+1,0Fm−1Anmk1,n−1+An−1mk2,n−2+⋯+A3mkn−2,2+A2mkn−1,1+mkn,0Anmk1,n−2+An−1mk2,n−3+⋯+A3mkn−2,1+A2mkn−1,0⋮Anmk1,00⋮0], |
F1=[kn,n+kn+1,nkn+1,nkn,n−1+kn+1,n−1kn+1,n−1⋮⋮kn,1+kn+1,1kn+1,1kn,0kn+1,0]. |
By Lemma 1, it follows that if and only if it satisfies
kn+1,n=0,rank(^Fm)=rank(Fm), |
There exist mth polynomial particular solutions to the nth-order VCHDE (3.1) with the coefficients (3.2).
Proof completed (PC).
We can now extend the conclusions about the specific solutions of the fourth-order VCHDE (2.1) to the conclusions about the specific solutions of the nth-order VCHDE (3.1), and therefore the following conclusions can be proved as well.
Theorem 5. When kn,n≠0, there is a unique number of polynomial particular solutions to VCHDE (3.1) with nth-order polynomial coefficients of (3.2).
Corollary 4. When kn,n≠0, the sufficiently and necessary condition for the existence of mth-order polynomial particular solutions to the nth-order VCHDE (3.1) with the coefficients (3.2) is
m=−kn+1,n−1kn,n∈N+rank(^Fm)=m, |
where ^Fm is the matrix obtained by removing the first row of Fm.
Theorem 6. When kn−1,n≠0, the sufficient and necessary condition for the coefficients (3.2) of nth-order VCHDE (3.1) to have two linearly independent particular solutions is
kn,n=kn+1,n=kn+1,n−1=0, |
h(x)=A2mkn−1,n+mkn,n−1+kn+1,n−2, |
has two positive integer roots m1,m2, where m1≠m2, and
rank(Fm1)=rank(Fm1−1),rank(Fm2)=rank(Fm2−1). |
Corollary 5. When kn−2,n≠0, the sufficiently necessary condition for an nth-order VCHDE (3.1) with the coefficients (3.2) to have three linearly independent particular solutions is
kn,n=kn+1,n=kn+1,n−1=0, |
kn−1,n=kn,n−1=kn+1,n−2=0, |
h1(x)=A3mkn−2,n+A2mkn−1,n−1+mkn,n−2+kn+1,n−3, |
where there exist three positive integer roots m1,m2,m3, where m1,m2,m3 are pairwise distinct, and
rank(Fm1)=rank(Fm1−2),rank(Fm2)=rank(Fm2−2),rank(Fm3)=rank(Fm3−2). |
Corollary 6. When kn−3,n≠0, the sufficiently necessary condition for a fourth-order VCHDE (3.1) with the coefficients (3.2) to have four linearly independent particular solutions is
kn,n=kn+1,n=kn+1,n−1=0, |
kn−1,n=kn,n−1=kn+1,n−2=0, |
kn−2,n=kn−1,n−1=kn,n−2=kn+1,n−3=0, |
h2(x)=A4mkn−3,n+A3mkn−2,n−1+A2mkn−1,n−2+mkn,n−3+kn+1,n−4, |
where there exist four positive integer roots m1,m2,m3,m4, where m1,m2,m3,m4 are pairwise distinct, and
rank(Fm1)=rank(Fm1−3),rank(Fm2)=rank(Fm2−3),rank(Fm3)=rank(Fm3−3),rank(Fm4)=rank(Fm4−3). |
In this work, we used the lemma about the necessary and sufficient conditions for the existence of the solutions of homogeneous differential equations, and the relationship between the coefficient matrix of VCHDE and the existence of polynomial particular solutions was studied. Especially, compared with prior works [30,31], this work extends, for the first time, the necessary and sufficient conditions for the existence of particular solutions of VCHDE to the fourth-order and nth-order cases. The main results are as follows:
(1) The necessary and sufficient conditions for the existence of solutions of fourth-order variable coefficient VCHDE and the necessary and sufficient conditions for the existence of solutions of nth-order VCHDE were obtained.
(2) The necessary and sufficient conditions for the existence of only one polynomial particular solution, or the existence of two, three, or four linearly independent polynomial particular solutions of fourth-order VCHDE are proved.
(3) The necessary and sufficient conditions for the existence of only one polynomial particular solution, or the existence of two, three, or four linearly independent polynomial particular solutions of nth-order VCHDE are proved.
These results not only expand the class of solvable differential equations but also provide a new way of thinking about the existence of solutions to polynomial coefficient VCHDE and a systematic and unified analytical framework for studying VCHDE.
However, the results of this work have not yet been validated numerically, and we plan to validate the results in future work. Many early studies have demonstrated that numerical validation methods are indeed feasible. Hu designed an algorithm to automatically determine and solve the polynomial particular or general solutions of the equation [30]. The algorithm judges and calculates on the basis of the equation's coefficient conditions, including evaluating the polynomial coefficient values, calculating the roots of relevant functions, and constructing matrices to determine the rank and determinant. Examples are verified in Maple software. Li designed an algorithm for solving the third-order VCHDE with polynomial coefficients [31]. The process entails inputting the polynomial coefficients, making multi-step judgments according to the coefficients' conditions, such as verifying that the coefficient elements are zero, calculating the roots of relevant functions, and constructing matrices to judge the rank, ultimately outputting the expressions of particular or general solutions. MATLAB software is used to solve and verify specific examples. Specifically, by substituting specific coefficient values into the equation and employing numerical computation methods to solve it, followed by comparing the outcomes with the theoretical results, the existence of particular solutions under various conditions can be vividly illustrated. Thus, this method can be applied in our future validation work.
Additionally, the current work has limitations in terms of the polynomial coefficients and the number of linearly independent solutions. Therefore, we plan to address these limitations in future work. On one hand, we will consider various types of VCHDE, including those with non-polynomial coefficients, such as exponential and trigonometric functions, and explore the feasibility of establishing similar conditions for the existence of solutions. On the other hand, the influence of boundary value conditions on the equations is an important aspect. If VCHDEs 2.1 and 3.1 are subject to boundary value conditions, they may alter the existence and uniqueness of solutions, requiring reanalysis and the derivation of relevant conclusions. Zhao et al. confirmed that the interaction between boundary value conditions and the rank of the coefficient matrix has a significant effect on VCHDE [2].
The theoretical results presented in this work have potential applications to real-world problems. In materials science, VCHDE can describe processes like heat conduction and mass diffusion in materials, with coefficients varying according to the material's physical properties. Wang's optical system design research shows precise analysis of differential equation solutions' properties is crucial in material physical process modeling. This study's results help determine the heat conduction equation solutions' existence, the aiding understanding of heat transfer in alloys [1]. In communication, signal propagation models in complex media often involve VCHDE. For instance, in time-varying channels, signal attenuation and velocity may change with time or space. Zhang et al.'s research on nonlinear differential equation solutions shows that this study's findings may help analyze propagation model solutions' characteristics, providing theoretical support for signal processing and communication system design [20]. However, further in-depth studies and real-data verification are needed for specific applications.
The first author was mainly responsible for the formulas' derivation and programming. The second author guided the crucial steps from theoretical hypothesis to derivation of the conclusion. The third author participated in the writing and review of the paper. The fourth author provided technical support for the research. The fifth author was in charge of the literature research and data analysis. The sixth author took part in the formulation of the research plan.
The authors declare they have not used artificial intelligence (AI) tools in the creation of this article.
We thank the anonymous referee for valuable and helpful comments and suggestions. This work is supported by the National Nature Science Foundation of China (12463009), the Yunnan Fundamental Research Projects (grant Nos. 202301AV070007, 202401AU070026, 202401AT070955, and 202401AU070296), the "Yunnan Revitalization Talent Support Program" Innovation Team Project (grant No. 202405AS350012), the Scientific Research Foundation Project of Yunnan Education Department (2023J0624, 2024Y469, 2025Y0720, 2025Y0721, and 2025J0502), and the GHfund A (202407016295).
All authors declare no conflicts of interest in this paper.
[1] |
Cheung AK, Sarnak MJ, Yan G, et al. (2004) Cardiac diseases in maintenance hemodialysis patients: results of the HEMO Study. Kidney Int 65: 2380-2389. doi: 10.1111/j.1523-1755.2004.00657.x
![]() |
[2] |
Foley RN, Parfrey PS, Harnett JD, et al. (1995) Clinical and echocardiographic disease in patients starting end-stage renal disease therapy. Kidney Int 47: 186-192. doi: 10.1038/ki.1995.22
![]() |
[3] | ANZDATA Registry. 38th Report, Chapter 3: Mortality in End Stage Kidney Disease. Australia and New Zealand Dialysis and Transplant Registry, Adelaide, Australia. 2016. |
[4] |
Foley RN, Parfrey PS, Sarnak MJ (1998) Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 32: S112-119. doi: 10.1053/ajkd.1998.v32.pm9820470
![]() |
[5] |
Longenecker JC, Coresh J, Powe NR, et al. (2002) Traditional cardiovascular disease risk factors in dialysis patients compared with the general population: the CHOICE Study. J Am Soc Nephrol 13: 1918-1927. doi: 10.1097/01.ASN.0000019641.41496.1E
![]() |
[6] |
Ruilope LM, van Veldhuisen DJ, Ritz E, et al. (2001) Renal function: the Cinderella of cardiovascular risk profile. J Am Coll Cardiol 38: 1782-1787. doi: 10.1016/S0735-1097(01)01627-8
![]() |
[7] |
Agarwal R (2005) Hypertension in chronic kidney disease and dialysis: pathophysiology and management. Cardiol Clin 23: 237-248. doi: 10.1016/j.ccl.2005.03.003
![]() |
[8] |
Neumann J, Ligtenberg G, Klein II, et al. (2004) Sympathetic hyperactivity in chronic kidney disease: pathogenesis, clinical relevance, and treatment. Kidney Int 65: 1568-1576. doi: 10.1111/j.1523-1755.2004.00552.x
![]() |
[9] |
Covic A, Kothawala P, Bernal M, et al. (2009) Systematic review of the evidence underlying the association between mineral metabolism disturbances and risk of all-cause mortality, cardiovascular mortality and cardiovascular events in chronic kidney disease. Nephrol Dial Transplant 24: 1506-1523. doi: 10.1093/ndt/gfn613
![]() |
[10] |
Kaysen GA, Eiserich JP (2004) The role of oxidative stress-altered lipoprotein structure and function and microinflammation on cardiovascular risk in patients with minor renal dysfunction. J Am Soc Nephrol 15: 538-548. doi: 10.1097/01.ASN.0000111744.00916.E6
![]() |
[11] |
Wang AY, Lam CW, Chan IH, et al. (2010) Sudden cardiac death in end-stage renal disease patients: a 5-year prospective analysis. Hypertension 56: 210-216. doi: 10.1161/HYPERTENSIONAHA.110.151167
![]() |
[12] | Martinez-Rumayor A, Richards AM, Burnett JC, et al. (2008) Biology of the natriuretic peptides. Am J Cardiol 101: 3-8. |
[13] | Mukoyama M, Nakao K, Hosoda K, et al. (1991) Brain natriuretic peptide as a novel cardiac hormone in humans. Evidence for an exquisite dual natriuretic peptide system, atrial natriuretic peptide and brain natriuretic peptide. J Clin Invest 87: 1402-1412. |
[14] |
Yasue H, Yoshimura M, Sumida H, et al. (1994) Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure. Circulation 90: 195-203. doi: 10.1161/01.CIR.90.1.195
![]() |
[15] | Gerbes AL, Dagnino L, Nguyen T, et al. (1994) Transcription of brain natriuretic peptide and atrial natriuretic peptide genes in human tissues. J Clin Endocrinol Metab 78: 1307-1311. |
[16] | Kinnunen P, Vuolteenaho O, Ruskoaho H (1993) Mechanisms of atrial and brain natriuretic peptide release from rat ventricular myocardium: effect of stretching. Endocrinology 132: 1961-1970. |
[17] | Bruneau BG, Piazza LA, de Bold AJ (1997) BNP gene expression is specifically modulated by stretch and ET-1 in a new model of isolated rat atria. Am J Physiol 273: H2678-2686. |
[18] |
Liang F, Gardner DG (1999) Mechanical strain activates BNP gene transcription through a p38/NF-kappaB-dependent mechanism. J Clin Invest 104: 1603-1612. doi: 10.1172/JCI7362
![]() |
[19] |
Bibbins-Domingo K, Ansari M, Schiller NB, et al. (2003) B-type natriuretic peptide and ischemia in patients with stable coronary disease: data from the Heart and Soul study. Circulation 108: 2987-2992. doi: 10.1161/01.CIR.0000103681.04726.9C
![]() |
[20] |
de Bold AJ (2009) Cardiac natriuretic peptides gene expression and secretion in inflammation. J Investig Med 57: 29-32. doi: 10.2310/JIM.0b013e3181948b37
![]() |
[21] | Bruneau BG, Piazza LA, de Bold AJ (1996) Alpha 1-adrenergic stimulation of isolated rat atria results in discoordinate increases in natriuretic peptide secretion and gene expression and enhances Egr-1 and c-Myc expression. Endocrinology 137: 137-143. |
[22] |
Wiese S, Breyer T, Dragu A, et al. (2000) Gene expression of brain natriuretic peptide in isolated atrial and ventricular human myocardium: influence of angiotensin II and diastolic fiber length. Circulation 102: 3074-3079. doi: 10.1161/01.CIR.102.25.3074
![]() |
[23] |
Maisel AS, Krishnaswamy P, Nowak RM, et al. (2002) Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 347: 161-167. doi: 10.1056/NEJMoa020233
![]() |
[24] |
McCullough PA, Nowak RM, McCord J, et al. (2002) B-type natriuretic peptide and clinical judgment in emergency diagnosis of heart failure: analysis from Breathing Not Properly (BNP) Multinational Study. Circulation 106: 416-422. doi: 10.1161/01.CIR.0000025242.79963.4C
![]() |
[25] |
Doust JA, Pietrzak E, Dobson A, et al. (2005) How well does B-type natriuretic peptide predict death and cardiac events in patients with heart failure: systematic review. Bmj 330: 625. doi: 10.1136/bmj.330.7492.625
![]() |
[26] |
Troughton RW, Frampton CM, Yandle TG, et al. (2000) Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet 355: 1126-1130. doi: 10.1016/S0140-6736(00)02060-2
![]() |
[27] |
Pfisterer M, Buser P, Rickli H, et al. (2009) BNP-guided vs symptom-guided heart failure therapy: the Trial of Intensified vs Standard Medical Therapy in Elderly Patients With Congestive Heart Failure (TIME-CHF) randomized trial. Jama 301: 383-392. doi: 10.1001/jama.2009.2
![]() |
[28] |
Berger R, Moertl D, Peter S, et al. (2010) N-terminal pro-B-type natriuretic peptide-guided, intensive patient management in addition to multidisciplinary care in chronic heart failure a 3-arm, prospective, randomized pilot study. J Am Coll Cardiol 55: 645-653. doi: 10.1016/j.jacc.2009.08.078
![]() |
[29] |
Eurlings LW, van Pol PE, Kok WE, et al. (2010) Management of chronic heart failure guided by individual N-terminal pro-B-type natriuretic peptide targets: results of the PRIMA (Can PRo-brain-natriuretic peptide guided therapy of chronic heart failure IMprove heart fAilure morbidity and mortality?) study. J Am Coll Cardiol 56: 2090-2100. doi: 10.1016/j.jacc.2010.07.030
![]() |
[30] |
Persson H, Erntell H, Eriksson B, et al. (2010) Improved pharmacological therapy of chronic heart failure in primary care: a randomized Study of NT-proBNP Guided Management of Heart Failure--SIGNAL-HF (Swedish Intervention study—Guidelines and NT-proBNP AnaLysis in Heart Failure). Eur J Heart Fail 12: 1300-1308. doi: 10.1093/eurjhf/hfq169
![]() |
[31] |
Lainchbury JG, Troughton RW, Strangman KM, et al. (2009) N-terminal pro-B-type natriuretic peptide-guided treatment for chronic heart failure: results from the BATTLESCARRED (NT-proBNP-Assisted Treatment To Lessen Serial Cardiac Readmissions and Death) trial. J Am Coll Cardiol 55: 53-60. doi: 10.1016/j.jacc.2009.02.095
![]() |
[32] |
Shah MR, Califf RM, Nohria A, et al. (2011) The STARBRITE trial: a randomized, pilot study of B-type natriuretic peptide-guided therapy in patients with advanced heart failure. J Card Fail 17: 613-621. doi: 10.1016/j.cardfail.2011.04.012
![]() |
[33] |
Karlstrom P, Alehagen U, Boman K, et al. (2011) Brain natriuretic peptide-guided treatment does not improve morbidity and mortality in extensively treated patients with chronic heart failure: responders to treatment have a significantly better outcome. Eur J Heart Fail 13: 1096-1103. doi: 10.1093/eurjhf/hfr078
![]() |
[34] |
Januzzi JL, Jr., Rehman SU, Mohammed AA, et al. (2011) Use of amino-terminal pro-B-type natriuretic peptide to guide outpatient therapy of patients with chronic left ventricular systolic dysfunction. J Am Coll Cardiol 58: 1881-1889. doi: 10.1016/j.jacc.2011.03.072
![]() |
[35] |
Jourdain P, Jondeau G, Funck F, et al. (2007) Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure: the STARS-BNP Multicenter Study. J Am Coll Cardiol 49: 1733-1739. doi: 10.1016/j.jacc.2006.10.081
![]() |
[36] |
Anguita M, Esteban F, Castillo JC, et al. (2010) [Usefulness of brain natriuretic peptide levels, as compared with usual clinical control, for the treatment monitoring of patients with heart failure]. Med Clin (Barc) 135: 435-440. doi: 10.1016/j.medcli.2009.11.048
![]() |
[37] |
Troughton RW, Frampton CM, Brunner-La Rocca HP, et al. (2014) Effect of B-type natriuretic peptide-guided treatment of chronic heart failure on total mortality and hospitalization: an individual patient meta-analysis. Eur Heart J 35: 1559-1567. doi: 10.1093/eurheartj/ehu090
![]() |
[38] |
Mant J, Al-Mohammad A, Swain S, et al. (2011) Management of chronic heart failure in adults: synopsis of the National Institute For Health and clinical excellence guideline. Ann Intern Med 155: 252-259. doi: 10.7326/0003-4819-155-4-201108160-00009
![]() |
[39] |
van Kimmenade RR, Januzzi JL, Jr., Bakker JA, et al. (2009) Renal clearance of B-type natriuretic peptide and amino terminal pro-B-type natriuretic peptide a mechanistic study in hypertensive subjects. J Am Coll Cardiol 53: 884-890. doi: 10.1016/j.jacc.2008.11.032
![]() |
[40] |
Tsai SH, Lin YY, Chu SJ, et al. (2010) Interpretation and use of natriuretic peptides in non-congestive heart failure settings. Yonsei Med J 51: 151-163. doi: 10.3349/ymj.2010.51.2.151
![]() |
[41] | Januzzi JL, van Kimmenade R, Lainchbury J, et al. (2006) NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients: the International Collaborative of NT-proBNP Study. Eur Heart J 27: 330-337. |
[42] |
Gutierrez OM, Tamez H, Bhan I, et al. (2008) N-terminal pro-B-type natriuretic peptide (NT-proBNP) concentrations in hemodialysis patients: prognostic value of baseline and follow-up measurements. Clin Chem 54: 1339-1348. doi: 10.1373/clinchem.2007.101691
![]() |
[43] |
Wang AY, Lam CW, Yu CM, et al. (2007) N-terminal pro-brain natriuretic peptide: an independent risk predictor of cardiovascular congestion, mortality, and adverse cardiovascular outcomes in chronic peritoneal dialysis patients. J Am Soc Nephrol 18: 321-330. doi: 10.1681/ASN.2005121299
![]() |
[44] |
Satyan S, Light RP, Agarwal R (2007) Relationships of N-terminal pro-B-natriuretic peptide and cardiac troponin T to left ventricular mass and function and mortality in asymptomatic hemodialysis patients. Am J Kidney Dis 50: 1009-1019. doi: 10.1053/j.ajkd.2007.08.017
![]() |
[45] |
Paniagua R, Amato D, Mujais S, et al. (2008) Predictive value of brain natriuretic peptides in patients on peritoneal dialysis: results from the ADEMEX trial. Clin J Am Soc Nephrol 3: 407-415. doi: 10.2215/CJN.03820907
![]() |
[46] | David S, Kumpers P, Seidler V, et al. (2008) Diagnostic value of N-terminal pro-B-type natriuretic peptide (NT-proBNP) for left ventricular dysfunction in patients with chronic kidney disease stage 5 on haemodialysis. Nephrol Dial Transplant 23: 1370-1377. |
[47] | Parfrey PS (2000) Cardiac disease in dialysis patients: diagnosis, burden of disease, prognosis, risk factors and management. Nephrol Dial Transplant 15 Suppl 5: 58-68. |
[48] |
Fahim MA, Hayen A, Horvath AR, et al. (2015) N-terminal pro-B-type natriuretic peptide variability in stable dialysis patients. Clin J Am Soc Nephrol 10: 620-629. doi: 10.2215/CJN.09060914
![]() |
[49] | Lippi G, Tessitore N, Luca Salvagno G, et al. (2007) Influence of haemodialysis on the NT-proBNP plasma concentration. Clin Chem Lab Med 45: 1414-1415. |
[50] |
Wahl HG, Graf S, Renz H, et al. (2004) Elimination of the cardiac natriuretic peptides B-type natriuretic peptide (BNP) and N-terminal proBNP by hemodialysis. Clin Chem 50: 1071-1074. doi: 10.1373/clinchem.2003.030692
![]() |
[51] |
Clerico A, Caprioli R, Del Ry S, et al. (2001) Clinical relevance of cardiac natriuretic peptides measured by means of competitive and non-competitive immunoassay methods in patients with renal failure on chronic hemodialysis. J Endocrinol Invest 24: 24-30. doi: 10.1007/BF03343804
![]() |
[52] |
Racek J, Kralova H, Trefil L, et al. (2006) Brain natriuretic peptide and N-terminal proBNP in chronic haemodialysis patients. Nephron Clin Pract 103: c162-172. doi: 10.1159/000092914
![]() |
[53] |
Dautin G, Boudjeltia S, Soltani Z, et al. (2007) The changes in NT-proBNP plasma concentrations during dialysis are highly dependent of the dialysis membrane ultrafiltration coefficient. Clin Chim Acta 376: 237-239. doi: 10.1016/j.cca.2006.08.004
![]() |
[54] | Bargnoux AS, Klouche K, Fareh J, et al. (2008) Prohormone brain natriuretic peptide (proBNP), BNP and N-terminal-proBNP circulating levels in chronic hemodialysis patients. Correlation with ventricular function, fluid removal and effect of hemodiafiltration. Clin Chem Lab Med 46: 1019-1024. |
[55] | Sheen V, Bhalla V, Tulua-Tata A, et al. (2007) The use of B-type natriuretic peptide to assess volume status in patients with end-stage renal disease. Am Heart J 153: 244.e241-245. |
[56] |
Flemmer M, Rajab H, Mathena T, et al. (2008) Blood B-type natriuretic peptide and dialysis: present assessment and future analyses. South Med J 101: 1094-1100. doi: 10.1097/SMJ.0b013e318189aa56
![]() |
[57] | Chiarelli G, Beaulieu M, Taylor P, et al. (2011) Elimination of BNP by peritoneal dialysis: investigation of analytical issues. Perit Dial Int 31: 199-202. |
[58] |
Obineche EN, Pathan JY, Fisher S, et al. (2006) Natriuretic peptide and adrenomedullin levels in chronic renal failure and effects of peritoneal dialysis. Kidney Int 69: 152-156. doi: 10.1038/sj.ki.5000009
![]() |
[59] | Granja CA, Tailor PT, Gorban-Brennan N, et al. (2007) Brain natriuretic peptide and impedance cardiography to assess volume status in peritoneal dialysis patients. Adv Perit Dial 23: 155-160. |
[60] | Lee JA, Kim DH, Yoo SJ, et al. (2006) Association between serum n-terminal pro-brain natriuretic peptide concentration and left ventricular dysfunction and extracellular water in continuous ambulatory peritoneal dialysis patients. Perit Dial Int 26: 360-365. |
[61] |
Booth J, Pinney J, Davenport A (2010) N-terminal proBNP--marker of cardiac dysfunction, fluid overload, or malnutrition in hemodialysis patients? Clin J Am Soc Nephrol 5: 1036-1040. doi: 10.2215/CJN.09001209
![]() |
[62] | Gangji AS, Helal BA, Churchill DN, et al. (2008) Association between N-terminal propeptide B-type natriuretic peptide and markers of hypervolemia. Perit Dial Int 28: 308-311. |
[63] |
Jacobs LH, van de Kerkhof JJ, Mingels AM, et al. (2010) Inflammation, overhydration and cardiac biomarkers in haemodialysis patients: a longitudinal study. Nephrol Dial Transplant 25: 243-248. doi: 10.1093/ndt/gfp417
![]() |
[64] |
Lee SW, Song JH, Kim GA, et al. (2003) Plasma brain natriuretic peptide concentration on assessment of hydration status in hemodialysis patient. Am J Kidney Dis 41: 1257-1266. doi: 10.1016/S0272-6386(03)00358-5
![]() |
[65] | Fagugli RM, Palumbo B, Ricciardi D, et al. (2003) Association between brain natriuretic peptide and extracellular water in hemodialysis patients. Nephron Clin Pract 95: c60-66. |
[66] |
Sommerer C, Beimler J, Schwenger V, et al. (2007) Cardiac biomarkers and survival in haemodialysis patients. Eur J Clin Invest 37: 350-356. doi: 10.1111/j.1365-2362.2007.01785.x
![]() |
[67] | Bavbek N, Akay H, Altay M, et al. (2007) Serum BNP concentration and left ventricular mass in CAPD and automated peritoneal dialysis patients. Perit Dial Int 27: 663-668. |
[68] | Zoccali C, Mallamaci F, Benedetto FA, et al. (2001) Cardiac natriuretic peptides are related to left ventricular mass and function and predict mortality in dialysis patients. J Am Soc Nephrol 12: 1508-1515. |
[69] |
Foley RN, Curtis BM, Randell EW, et al. (2010) Left ventricular hypertrophy in new hemodialysis patients without symptomatic cardiac disease. Clin J Am Soc Nephrol 5: 805-813. doi: 10.2215/CJN.07761109
![]() |
[70] |
Mallamaci F, Zoccali C, Tripepi G, et al. (2001) Diagnostic potential of cardiac natriuretic peptides in dialysis patients. Kidney Int 59: 1559-1566. doi: 10.1046/j.1523-1755.2001.0590041559.x
![]() |
[71] |
Choi SY, Lee JE, Jang EH, et al. (2008) Association between changes in N-terminal pro-brain natriuretic peptide levels and changes in left ventricular mass index in stable hemodialysis patients. Nephron Clin Pract 110: c93-100. doi: 10.1159/000157622
![]() |
[72] |
Takase H, Dohi Y, Toriyama T, et al. (2011) B-type natriuretic peptide levels and cardiovascular risk in patients with diastolic dysfunction on chronic haemodialysis: cross-sectional and observational studies. Nephrol Dial Transplant 26: 683-690. doi: 10.1093/ndt/gfq408
![]() |
[73] |
Goto T, Takase H, Toriyama T, et al. (2002) Increased circulating levels of natriuretic peptides predict future cardiac event in patients with chronic hemodialysis. Nephron 92: 610-615. doi: 10.1159/000064100
![]() |
[74] |
Tripepi G, Mattace-Raso F, Mallamaci F, et al. (2009) Biomarkers of left atrial volume: a longitudinal study in patients with end stage renal disease. Hypertension 54: 818-824. doi: 10.1161/HYPERTENSIONAHA.109.136804
![]() |
[75] |
Wang AY, Wang M, Lam CW, et al. (2011) Heart failure in long-term peritoneal dialysis patients: a 4-year prospective analysis. Clin J Am Soc Nephrol 6: 805-812. doi: 10.2215/CJN.07130810
![]() |
[76] |
Winkler K, Wanner C, Drechsler C, et al. (2008) Change in N-terminal-pro-B-type-natriuretic-peptide and the risk of sudden death, stroke, myocardial infarction, and all-cause mortality in diabetic dialysis patients. Eur Heart J 29: 2092-2099. doi: 10.1093/eurheartj/ehn278
![]() |
[77] |
Breidthardt T, Kalbermatter S, Socrates T, et al. (2011) Increasing B-type natriuretic peptide levels predict mortality in unselected haemodialysis patients. Eur J Heart Fail 13: 860-867. doi: 10.1093/eurjhf/hfr057
![]() |
[78] | Doust J (2010) Qualification versus validation of biomarkers. Scand J Clin Lab Invest Suppl 242: 40-43. |
[79] |
Katus HA, Remppis A, Scheffold T, et al. (1991) Intracellular compartmentation of cardiac troponin T and its release kinetics in patients with reperfused and nonreperfused myocardial infarction. Am J Cardiol 67: 1360-1367. doi: 10.1016/0002-9149(91)90466-X
![]() |
[80] |
Turer AT, Addo TA, Martin JL, et al. (2011) Myocardial ischemia induced by rapid atrial pacing causes troponin T release detectable by a highly sensitive assay: insights from a coronary sinus sampling study. J Am Coll Cardiol 57: 2398-2405. doi: 10.1016/j.jacc.2010.11.066
![]() |
[81] |
Hessel MH, Atsma DE, van der Valk EJ, et al. (2008) Release of cardiac troponin I from viable cardiomyocytes is mediated by integrin stimulation. Pflugers Arch 455: 979-986. doi: 10.1007/s00424-007-0354-8
![]() |
[82] |
Thygesen K, Alpert JS, Jaffe AS, et al. (2012) Third universal definition of myocardial infarction. Circulation 126: 2020-2035. doi: 10.1161/CIR.0b013e31826e1058
![]() |
[83] |
Keddis MT, El-Zoghby ZM, El Ters M, et al. (2013) Cardiac troponin T before and after kidney transplantation: determinants and implications for posttransplant survival. Am J Transplant 13: 406-414. doi: 10.1111/j.1600-6143.2012.04317.x
![]() |
[84] | Wu AH, Feng YJ, Roper L, et al. (1997) Cardiac troponins T and I before and after renal transplantation. Clin Chem 43: 411-412. |
[85] |
Fredericks S, Chang R, Gregson H, et al. (2001) Circulating cardiac troponin-T in patients before and after renal transplantation. Clin Chim Acta 310: 199-203. doi: 10.1016/S0009-8981(01)00547-2
![]() |
[86] |
Bozbas H, Korkmaz ME, Atar I, et al. (2004) Serum levels of cardiac enzymes before and after renal transplantation. Clin Cardiol 27: 559-562. doi: 10.1002/clc.4960271007
![]() |
[87] |
Ellis K, Dreisbach AW, Lertora JL (2001) Plasma elimination of cardiac troponin I in end-stage renal disease. South Med J 94: 993-996. doi: 10.1097/00007611-200194100-00011
![]() |
[88] |
Fahie-Wilson MN, Carmichael DJ, Delaney MP, et al. (2006) Cardiac troponin T circulates in the free, intact form in patients with kidney failure. Clin Chem 52: 414-420. doi: 10.1373/clinchem.2005.062307
![]() |
[89] |
Jacobs LH, van de Kerkhof J, Mingels AM, et al. (2009) Haemodialysis patients longitudinally assessed by highly sensitive cardiac troponin T and commercial cardiac troponin T and cardiac troponin I assays. Ann Clin Biochem 46: 283-290. doi: 10.1258/acb.2009.008197
![]() |
[90] |
Kumar N, Michelis MF, DeVita MV, et al. (2011) Troponin I levels in asymptomatic patients on haemodialysis using a high-sensitivity assay. Nephrol Dial Transplant 26: 665-670. doi: 10.1093/ndt/gfq442
![]() |
[91] |
Wolley M, Stewart R, Curry E, et al. (2013) Variation in and prognostic importance of troponin T measured using a high-sensitivity assay in clinically stable haemodialysis patients. Clin Kidney J 6: 402-409. doi: 10.1093/ckj/sfs122
![]() |
[92] |
Hill SA, Cleve R, Carlisle E, et al. (2009) Intra-individual variability in troponin T concentration in dialysis patients. Clin Biochem 42: 991-995. doi: 10.1016/j.clinbiochem.2009.03.027
![]() |
[93] |
Pianta TJ, Horvath AR, Ellis VM, et al. (2012) Cardiac high-sensitivity troponin T measurement: a layer of complexity in managing haemodialysis patients. Nephrology (Carlton) 17: 636-641. doi: 10.1111/j.1440-1797.2012.01625.x
![]() |
[94] | Katus HA, Haller C, Muller-Bardorff M, et al. (1995) Cardiac troponin T in end-stage renal disease patients undergoing chronic maintenance hemodialysis. Clin Chem 41: 1201-1203. |
[95] | Collinson PO, Stubbs PJ, Rosalki SB (1995) Cardiac troponin T in renal disease. Clin Chem 41: 1671-1673. |
[96] | Li D, Jialal I, Keffer J (1996) Greater frequency of increased cardiac troponin T than increased cardiac troponin I in patients with chronic renal failure. Clin Chem 42: 114-115. |
[97] |
Hickman PE, McGill D, Potter JM, et al. (2015) Multiple biomarkers including cardiac troponins T and I measured by high-sensitivity assays, as predictors of long-term mortality in patients with chronic renal failure who underwent dialysis. Am J Cardiol 115: 1601-1606. doi: 10.1016/j.amjcard.2015.02.066
![]() |
[98] | Lippi G, Tessitore N, Montagnana M, et al. (2008) Influence of sampling time and ultrafiltration coefficient of the dialysis membrane on cardiac troponin I and T. Arch Pathol Lab Med 132: 72-76. |
[99] |
Gaze DC, Collinson PO (2014) Cardiac troponin I but not cardiac troponin T adheres to polysulfone dialyser membranes in an in vitro haemodialysis model: explanation for lower serum cTnI concentrations following dialysis. Open Heart 1: e000108. doi: 10.1136/openhrt-2014-000108
![]() |
[100] | Nunes JP, Sampaio S, Cerqueira A, et al. (2015) Anti-troponin I antibodies in renal transplant patients. Rev Port Cardiol 34: 85-89. |
[101] |
Sacchetti A, Harris R, Patel K, et al. (1991) Emergency department presentation of renal dialysis patients: indications for EMS transport directly to dialysis centers. J Emerg Med 9: 141-144. doi: 10.1016/0736-4679(91)90320-F
![]() |
[102] |
McDonald SP, Tong B (2011) Morbidity burden of end-stage kidney disease in Australia: hospital separation rates among people receiving kidney replacement therapy. Nephrology (Carlton) 16: 758-766. doi: 10.1111/j.1440-1797.2011.01486.x
![]() |
[103] |
Herzog CA, Littrell K, Arko C, et al. (2007) Clinical characteristics of dialysis patients with acute myocardial infarction in the United States: a collaborative project of the United States Renal Data System and the National Registry of Myocardial Infarction. Circulation 116: 1465-1472. doi: 10.1161/CIRCULATIONAHA.107.696765
![]() |
[104] |
Sosnov J, Lessard D, Goldberg RJ, et al. (2006) Differential symptoms of acute myocardial infarction in patients with kidney disease: a community-wide perspective. Am J Kidney Dis 47: 378-384. doi: 10.1053/j.ajkd.2005.11.017
![]() |
[105] |
Jaffe AS, Apple FS (2012) The third Universal Definition of Myocardial Infarction--moving forward. Clin Chem 58: 1727-1728. doi: 10.1373/clinchem.2012.196832
![]() |
[106] |
Wu AH, Jaffe AS, Apple FS, et al. (2007) National Academy of Clinical Biochemistry laboratory medicine practice guidelines: use of cardiac troponin and B-type natriuretic peptide or N-terminal proB-type natriuretic peptide for etiologies other than acute coronary syndromes and heart failure. Clin Chem 53: 2086-2096. doi: 10.1373/clinchem.2007.095679
![]() |
[107] | Fahim MA, Hayen AD, Horvath AR, et al. (2015) Biological variation of high sensitivity cardiac troponin-T in stable dialysis patients: implications for clinical practice. Clin Chem Lab Med 53: 715-722. |
[108] |
Michos ED, Wilson LM, Yeh HC, et al. (2014) Prognostic value of cardiac troponin in patients with chronic kidney disease without suspected acute coronary syndrome: a systematic review and meta-analysis. Ann Intern Med 161: 491-501. doi: 10.7326/M14-0743
![]() |
[109] | (2005) K/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients. Am J Kidney Dis 45: S1-153. |
[110] |
Yancy CW, Jessup M, Bozkurt B, et al. (2013) 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 62: e147-239. doi: 10.1016/j.jacc.2013.05.019
![]() |
[111] |
Mueller T, Leitner I, Egger M, et al. (2015) Association of the biomarkers soluble ST2, galectin-3 and growth-differentiation factor-15 with heart failure and other non-cardiac diseases. Clin Chim Acta 445: 155-160. doi: 10.1016/j.cca.2015.03.033
![]() |
[112] |
Mueller T, Dieplinger B (2013) The Presage((R)) ST2 Assay: analytical considerations and clinical applications for a high-sensitivity assay for measurement of soluble ST2. Expert Rev Mol Diagn 13: 13-30. doi: 10.1586/erm.12.128
![]() |
[113] | Lippi G, Cervellin G (2014) Risk assessment of post-infarction heart failure. Systematic review on the role of emerging biomarkers. Crit Rev Clin Lab Sci 51: 13-29. |
[114] |
Weinberg EO, Shimpo M, De Keulenaer GW, et al. (2002) Expression and regulation of ST2, an interleukin-1 receptor family member, in cardiomyocytes and myocardial infarction. Circulation 106: 2961-2966. doi: 10.1161/01.CIR.0000038705.69871.D9
![]() |
[115] |
Demyanets S, Speidl WS, Tentzeris I, et al. (2014) Soluble ST2 and interleukin-33 levels in coronary artery disease: relation to disease activity and adverse outcome. PLoS One 9: e95055. doi: 10.1371/journal.pone.0095055
![]() |
[116] |
Dieplinger B, Egger M, Haltmayer M, et al. (2014) Increased soluble ST2 predicts long-term mortality in patients with stable coronary artery disease: results from the Ludwigshafen risk and cardiovascular health study. Clin Chem 60: 530-540. doi: 10.1373/clinchem.2013.209858
![]() |
[117] |
Bayes-Genis A, de Antonio M, Galan A, et al. (2012) Combined use of high-sensitivity ST2 and NTproBNP to improve the prediction of death in heart failure. Eur J Heart Fail 14: 32-38. doi: 10.1093/eurjhf/hfr156
![]() |
[118] | Lippi G, Salvagno GL, Robuschi F, et al. (2014) Influence of dipyridamole stress echocardiography on galectin-3, amino-terminal B-type natriuretic peptide (NT-proBNP) and high-sensitivity troponin T. Acta Cardiol 69: 377-383. |
[119] | Krzeslak A, Lipinska A (2004) Galectin-3 as a multifunctional protein. Cell Mol Biol Lett 9: 305-328. |
[120] |
Sharma UC, Pokharel S, van Brakel TJ, et al. (2004) Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction. Circulation 110: 3121-3128. doi: 10.1161/01.CIR.0000147181.65298.4D
![]() |
[121] | Suarez G, Meyerrose G (2014) Heart failure and galectin 3. Ann Transl Med 2: 86. |
[122] |
Chen A, Hou W, Zhang Y, et al. (2015) Prognostic value of serum galectin-3 in patients with heart failure: a meta-analysis. Int J Cardiol 182: 168-170. doi: 10.1016/j.ijcard.2014.12.137
![]() |
[123] |
Winter MP, Wiesbauer F, Alimohammadi A, et al. (2016) Soluble galectin-3 is associated with premature myocardial infarction. Eur J Clin Invest 46: 386-391. doi: 10.1111/eci.12605
![]() |
[124] |
Yancy CW, Jessup M, Bozkurt B, et al. (2013) 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 128: e240-327. doi: 10.1161/CIR.0b013e31829e8776
![]() |
[125] |
Hogas S, Schiller A, Voroneanu L, et al. (2016) Predictive Value for Galectin 3 and Cardiotrophin 1 in Hemodialysis Patients. Angiology 67: 854-859. doi: 10.1177/0003319715623397
![]() |
[126] |
Gurel OM, Yilmaz H, Celik TH, et al. (2015) Galectin-3 as a new biomarker of diastolic dysfunction in hemodialysis patients. Herz 40: 788-794. doi: 10.1007/s00059-015-4303-6
![]() |
[127] |
de Boer RA, van der Velde AR, Mueller C, et al. (2014) Galectin-3: a modifiable risk factor in heart failure. Cardiovasc Drugs Ther 28: 237-246. doi: 10.1007/s10557-014-6520-2
![]() |
[128] |
Hagstrom E, James SK, Bertilsson M, et al. (2016) Growth differentiation factor-15 level predicts major bleeding and cardiovascular events in patients with acute coronary syndromes: results from the PLATO study. Eur Heart J 37: 1325-1333. doi: 10.1093/eurheartj/ehv491
![]() |
[129] |
Jougasaki M, Rodeheffer RJ, Redfield MM, et al. (1996) Cardiac secretion of adrenomedullin in human heart failure. J Clin Invest 97: 2370-2376. doi: 10.1172/JCI118680
![]() |
[130] |
Nishikimi T, Saito Y, Kitamura K, et al. (1995) Increased plasma levels of adrenomedullin in patients with heart failure. J Am Coll Cardiol 26: 1424-1431. doi: 10.1016/0735-1097(95)00338-X
![]() |
[131] |
Maisel A, Mueller C, Nowak R, et al. (2010) Mid-region pro-hormone markers for diagnosis and prognosis in acute dyspnea: results from the BACH (Biomarkers in Acute Heart Failure) trial. J Am Coll Cardiol 55: 2062-2076. doi: 10.1016/j.jacc.2010.02.025
![]() |
[132] |
Giannopoulos G, Deftereos S, Panagopoulou V, et al. (2013) Copeptin as a biomarker in cardiac disease. Curr Top Med Chem 13: 231-240. doi: 10.2174/15680266113139990088
![]() |
[133] | Reid P, Holen I (2009) Pathophysiological roles of osteoprotegerin (OPG). Eur J Cell Biol 88: 1-17. |
[134] |
Nybo M, Rasmussen LM (2008) The capability of plasma osteoprotegerin as a predictor of cardiovascular disease: a systematic literature review. Eur J Endocrinol 159: 603-608. doi: 10.1530/EJE-08-0554
![]() |
[135] |
Rosenberg M, Zugck C, Nelles M, et al. (2008) Osteopontin, a new prognostic biomarker in patients with chronic heart failure. Circ Heart Fail 1: 43-49. doi: 10.1161/CIRCHEARTFAILURE.107.746172
![]() |
[136] |
Rabin KR, Kamari Y, Avni I, et al. (2005) Adiponectin: linking the metabolic syndrome to its cardiovascular consequences. Expert Rev Cardiovasc Ther 3: 465-471. doi: 10.1586/14779072.3.3.465
![]() |
[137] | Zoccali C, Mallamaci F, Panuccio V, et al. (2003) Adiponectin is markedly increased in patients with nephrotic syndrome and is related to metabolic risk factors. Kidney Int Suppl: S98-102. |
[138] | Zoccali C, Mallamaci F, Tripepi G, et al. (2002) Adiponectin, metabolic risk factors, and cardiovascular events among patients with end-stage renal disease. J Am Soc Nephrol 13: 134-141. |
[139] |
Yan AT, Yan RT, Spinale FG, et al. (2006) Plasma matrix metalloproteinase-9 level is correlated with left ventricular volumes and ejection fraction in patients with heart failure. J Card Fail 12: 514-519. doi: 10.1016/j.cardfail.2006.05.012
![]() |
[140] | Kecebas M, Gullulu S, Sag S, et al. (2014) Serum fetuin-A levels in patients with systolic heart failure. Acta Cardiol 69: 399-405. |
[141] |
Morrow DA, Cannon CP, Rifai N, et al. (2001) Ability of minor elevations of troponins I and T to predict benefit from an early invasive strategy in patients with unstable angina and non-ST elevation myocardial infarction: results from a randomized trial. Jama 286: 2405-2412. doi: 10.1001/jama.286.19.2405
![]() |
[142] |
Sandoval Y, Herzog CA, Love SA, et al. (2016) Prognostic Value of Serial Changes in High-Sensitivity Cardiac Troponin I and T over 3 Months Using Reference Change Values in Hemodialysis Patients. Clin Chem 62: 631-638. doi: 10.1373/clinchem.2015.251835
![]() |